PDS Biotechnology Corp Increase (Decrease) in Accrued Liabilities
PDS Biotechnology Corp (PDSB) reported Increase (Decrease) in Accrued Liabilities of $240.80 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2022-11-14
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was $125.58K, a 72.34% decline year-over-year.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for the quarter ending 2022-06-30 was $341.45K.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for the quarter ending 2022-03-31 was -$226.24K, a 289.36% decline year-over-year.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for the quarter ending 2021-09-30 was $454.05K, a 1497.94% increase year-over-year.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for fiscal 2018 was -$5.00M, a 326.54% decline from fiscal 2017.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for fiscal 2017 was $2.21M.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for fiscal 2016 was -$676.92K, a 131.60% decline from fiscal 2015.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities for fiscal 2015 was $2.14M, a 164.95% increase from fiscal 2014.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2022-09-30 | $125.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $467.04K derived: sum of 2 quarters · filed 2022-11-14 | $240.80K 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $341.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $115.22K 10-Q · filed 2022-08-08 | |||||
| 2022-03-31 | -$226.24K 10-Q · filed 2022-05-11 | ||||||
| 2021-09-30 | $454.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $69.05K derived: sum of 2 quarters · filed 2022-11-14 | $188.52K 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | -$385.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$265.53K 10-Q · filed 2022-08-08 | |||||
| 2021-03-31 | $119.47K 10-Q · filed 2022-05-11 | ||||||
| 2020-09-30 | $28.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.58K derived: sum of 2 quarters · filed 2021-11-10 | $125.13K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | -$25.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $96.72K 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | $122.55K 10-Q · filed 2021-05-13 | ||||||
| 2019-09-30 | -$607.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$596.18K derived: sum of 2 quarters · filed 2020-11-13 | -$900.62K 10-Q · filed 2020-11-13 | -$6.05M derived: sum of 4 quarters · filed 2020-11-13 | |||
| 2019-06-30 | $11.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$292.68K 10-Q · filed 2020-08-13 | -$5.44M derived: sum of 3 quarters · filed 2020-08-13 | -$5.52M derived: sum of 4 quarters · filed 2020-08-13 | |||
| 2019-03-31 | -$304.44K 10-Q · filed 2020-05-13 | -$5.45M derived: sum of 2 quarters · filed 2020-05-13 | -$5.54M derived: sum of 3 quarters · filed 2020-05-13 | -$5.60M derived: sum of 4 quarters · filed 2020-05-13 | |||
| 2018-12-31 | -$5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$5.23M derived: sum of 2 quarters · filed 2019-11-07 | -$5.29M derived: sum of 3 quarters · filed 2019-11-07 | -$5.00M 10-K · filed 2019-02-21 | |||
| 2018-09-30 | -$81.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$141.46K derived: sum of 2 quarters · filed 2019-11-07 | $146.56K 10-Q · filed 2019-11-07 | -$4.50M 10-Q · filed 2018-11-01 | $2.29M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | -$60.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $227.91K 10-Q · filed 2019-08-01 | $602.32K 10-Q · filed 2018-08-01 | $2.37M derived: sum of 3 quarters · filed 2019-08-01 | $1.50M derived: sum of 4 quarters · filed 2019-08-01 | ||
| 2018-03-31 | $288.02K 10-Q · filed 2019-05-14 | $3.05M 10-Q · filed 2018-05-01 | $2.43M derived: sum of 2 quarters · filed 2019-05-14 | $1.56M derived: sum of 3 quarters · filed 2019-05-14 | $2.19M derived: sum of 4 quarters · filed 2019-05-14 | ||
| 2017-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $1.27M derived: sum of 2 quarters · filed 2019-02-21 | $1.91M derived: sum of 3 quarters · filed 2019-02-21 | $2.21M 10-K · filed 2019-02-21 | |||
| 2017-09-30 | -$871.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$234.57K derived: sum of 2 quarters · filed 2018-11-01 | $68.68K 10-Q · filed 2018-11-01 | $860.87K derived: sum of 4 quarters · filed 2018-11-01 | |||
| 2017-06-30 | $637.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $940.30K 10-Q · filed 2018-08-01 | $1.73M derived: sum of 3 quarters · filed 2018-08-01 | $2.55M derived: sum of 4 quarters · filed 2018-08-01 | |||
| 2017-03-31 | $303.25K 10-Q · filed 2018-05-01 | $1.10M derived: sum of 2 quarters · filed 2018-05-01 | $1.91M derived: sum of 3 quarters · filed 2018-05-01 | $2.01M derived: sum of 4 quarters · filed 2018-05-01 | |||
| 2016-12-31 | $792.19K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $1.61M derived: sum of 2 quarters · filed 2018-03-01 | $1.70M derived: sum of 3 quarters · filed 2018-03-01 | -$676.92K 10-K · filed 2018-03-01 | |||
| 2016-09-30 | $813.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $911.97K derived: sum of 2 quarters · filed 2017-11-01 | -$1.47M 10-Q · filed 2017-11-01 | -$931.35K derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | $98.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$2.28M 10-Q · filed 2017-08-01 | -$1.74M derived: sum of 3 quarters · filed 2018-03-01 | $196.61K derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | -$2.38M 10-Q · filed 2017-05-03 | -$1.84M derived: sum of 2 quarters · filed 2018-03-01 | $98.00K derived: sum of 3 quarters · filed 2018-03-01 | -$754.12K derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $537.75K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $2.48M derived: sum of 2 quarters · filed 2018-03-01 | $1.63M derived: sum of 3 quarters · filed 2018-03-01 | $2.14M 10-K · filed 2018-03-01 | |||
| 2015-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $1.09M derived: sum of 2 quarters · filed 2016-11-01 | $1.60M 10-Q · filed 2016-11-01 | $2.42M derived: sum of 4 quarters · filed 2017-03-02 | |||
| 2015-06-30 | -$852.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$336.90K 10-Q · filed 2016-08-03 | $477.98K derived: sum of 3 quarters · filed 2017-03-02 | ||||
| 2015-03-31 | $515.23K 10-Q · filed 2016-05-03 | $1.33M derived: sum of 2 quarters · filed 2017-03-02 | |||||
| 2014-12-31 | $814.88K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $808.51K 10-K · filed 2017-03-02 | |||||
| 2014-09-30 | -$6.36K 10-Q · filed 2015-11-06 | ||||||
| 2013-12-31 | $100.82K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |